The lenvatinib target genes were significantly enriched in multiple pathways associated with tumor development and progression, such as the RTK–RAS–MAPK signaling pathway, the PI-3 kinase signaling pathway, the JAK–STAT signaling pathway, the cell cycle pathway, and the FGFR–FGF signaling pathway. The gene discussed is SOAT1; the disease is neoplasm.